A notable advancement in diabetes care is emerging with the release of tirzepatide at a dosage of 45mg. This innovative offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://macieugyk919227.dbblog.net/14100735/revolutionary-introduction-tirzepatide-45mg-for-diabetes-control